The first bellwether trial for Zofran birth defect lawsuits has been delayed until May while the FDA considers a citizen’s petition by GlaxoSmithKline on whether label warnings on the drug should be changed.…
Following a recent Supreme Court ruling, a federal judge is revisiting whether Zofran birth defect lawsuits should proceed as planned.…
Zofran lawsuits are continuing forward after a federal judge rejected calls by GlaxoSmithKline for a summary judgment in the manufacturer’s favor.…
A new study shows a link between Zofran use during pregnancy and an increased risk of oral cleft defects.…
A motion to dismiss all Zofran lawsuits claims that the FDA never allowed the manufacturer to put birth defect warning labels on the medication.…
Three Zofran birth defect lawsuits were dismissed by a federal judge who says GlaxoSmithKline cannot be held liable in cases where women used a generic version of the drug.…
Parties involved in Zofran litigation will select 16 potential bellwether cases by June 15 for claims dealing with heart and face birth defects.…
GlaxoSmithKline is accused of failing to turn over adverse event information which could indicate that the company knew that Zofran caused birth defects for years without warning pregnant women or the medical community.…
An effort by GlaxoSmithKline to dismiss fraud claims in Zofran birth defect lawsuits has been rejected by a federal judge overseeing the litigation.…
Treating birth defects costs the U.S. healthcare system as much as $23 billion every year, and accounts for one out of every $20 dollars spent on hospitalizations, according to a CDC study.…
